WO2013182828A1 - Dispersion aqueuse de particules de polymeres, composition filmogene la contenant et ses utilisations - Google Patents
Dispersion aqueuse de particules de polymeres, composition filmogene la contenant et ses utilisations Download PDFInfo
- Publication number
- WO2013182828A1 WO2013182828A1 PCT/FR2013/051325 FR2013051325W WO2013182828A1 WO 2013182828 A1 WO2013182828 A1 WO 2013182828A1 FR 2013051325 W FR2013051325 W FR 2013051325W WO 2013182828 A1 WO2013182828 A1 WO 2013182828A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aqueous dispersion
- polymer
- agents
- film
- sodium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F265/00—Macromolecular compounds obtained by polymerising monomers on to polymers of unsaturated monocarboxylic acids or derivatives thereof as defined in group C08F20/00
- C08F265/04—Macromolecular compounds obtained by polymerising monomers on to polymers of unsaturated monocarboxylic acids or derivatives thereof as defined in group C08F20/00 on to polymers of esters
- C08F265/06—Polymerisation of acrylate or methacrylate esters on to polymers thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/0279—Porous; Hollow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/18—Manufacture of films or sheets
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L101/00—Compositions of unspecified macromolecular compounds
- C08L101/12—Compositions of unspecified macromolecular compounds characterised by physical features, e.g. anisotropy, viscosity or electrical conductivity
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- C08L33/04—Homopolymers or copolymers of esters
- C08L33/06—Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, which oxygen atoms are present only as part of the carboxyl radical
- C08L33/08—Homopolymers or copolymers of acrylic acid esters
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- C08L33/04—Homopolymers or copolymers of esters
- C08L33/06—Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, which oxygen atoms are present only as part of the carboxyl radical
- C08L33/10—Homopolymers or copolymers of methacrylic acid esters
- C08L33/12—Homopolymers or copolymers of methyl methacrylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2300/00—Characterised by the use of unspecified polymers
- C08J2300/12—Polymers characterised by physical features, e.g. anisotropy, viscosity or electrical conductivity
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2400/00—Characterised by the use of unspecified polymers
- C08J2400/12—Polymers characterised by physical features, e.g. anisotropy, viscosity or electrical conductivity
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2207/00—Properties characterising the ingredient of the composition
- C08L2207/02—Heterophasic composition
Definitions
- the invention relates to an aqueous dispersion of multiphase particles of polymers, and to its use in film-forming compositions that may for example be applied to skin, mucous membranes, wounds, lesions and / or skin disorders.
- the invention also relates to the use of said dispersions to form physiologically acceptable films that can be applied to the skin.
- Physiologically acceptable formulations comprising latex type film forming compositions (aqueous polymer dispersions) are well known to those skilled in the art.
- compositions for use as a shaving foam comprises one or more film-forming materials dispersed in an aqueous phase by surfactants.
- the film-forming materials may be polymers such as polyvinylpyrrolidone or hydroxyethylcellulose or copolymers such as a styrene-acrylate or styrene-butadiene latex.
- surfactants are described such as in particular sarcosinic acid derivatives and more particularly sodium W-myristoylsarcosinate.
- the compositions according to this document are shaving foams and in particular do not make it possible to form an isolatable film which is elastic, water-resistant, which has good breaking strength and durably protects surfaces such as, for example, the skin.
- Latex may in particular be used to form isolable films.
- 3M discloses a latex composition comprising an aqueous copolymer dispersion comprising:
- a "soft" monomer whose homopolymer corresponds to a Tg of less than -15 ° C., such as butyl acrylate,
- a "hard” monomer whose homopolymer corresponds to a Tg greater than -5 ° C., such as methylmethacrylate, and
- composition also comprising iodine for its antimicrobial properties and for stabilizing the aqueous dispersion as well as a surfactant to help disperse the latex particles in the aqueous phase.
- iodine such as N-vinylpyrrolidinone
- This film-forming composition is intended to form a protective film on the skin, such as in particular a dressing.
- films formed using these compositions have limited mechanical properties, especially in terms of elasticity and breaking strength.
- the invention thus has, according to a first aspect of the invention, an aqueous dispersion of multiphase particles of polymers in which the polymer particles comprise at least two distinct phases:
- the invention also relates to a film-forming composition
- a film-forming composition comprising, in a physiologically acceptable medium, an aqueous dispersion of multiphase particles of polymers.
- the invention also relates, according to a 3 rd aspect, a film having at least two different Tg, said film comprising multiphase polymer particles and a surfactant, wherein the polymer particles comprise at least two distinct phases:
- said surfactant is selected from amino acid derivatives and wherein the polymer Pi is formed by polymerization in the presence of a crosslinking agent.
- the subject of the invention is the use of the film previously described, for protecting skin surfaces, mucous membranes, wounds, lesions and / or skin conditions.
- the present invention relates to an aqueous dispersion of multiphase particles of polymers.
- aqueous dispersion means a suspension of solid particles in a liquid phase comprising at least water.
- the aqueous phase also comprises at least one surfactant chosen from amino acid derivatives, and optionally an oxidation / reduction system and / or a pH regulator and / or one or more pharmaceutical or cosmetic agents and / or one or more physiologically additive additives. acceptable.
- the aqueous phase may especially be present in the dispersion according to the invention in a content ranging from 20 to 75%, preferably from 40 to 70% by weight, relative to the weight of the aqueous dispersion.
- Multiphasic polymer particles may especially be present in the dispersion according to the invention in a content ranging from 20 to 75%, preferably from 40 to 70% by weight, relative to the weight of the aqueous dispersion.
- the multiphase particles of polymers are solid particles of polymers which are dispersed in the aqueous phase.
- polymer is meant, in the sense of the present invention, a homopolymer or a copolymer.
- Said multiphasic particles comprise at least two phases, each phase consisting of a polymer having very distinct properties, such as, in particular, different glass transition temperatures (Tg) for each phase.
- Tg glass transition temperatures
- glass transition temperature (Tg) of each phase of multiphase polymer particles is meant either the Tg of the homopolymer as referenced in the literature, or the Tg of the copolymer calculated by the law of the Fox-Flory blends. Indeed, the Tg of each phase is not directly measurable on the multiphase particles as such.
- a phase of the particle consists of a copolymer
- the skilled person can easily calculate the Tg of this phase using in particular the law of Fox-Flory mixtures.
- Tg glass transition temperature
- AB glass transition temperature of the copolymer
- the first phase formed by the soft-matter polymer Pi may be the internal phase of the particle (also called the core) and the second phase formed by the hard-type polymer P 2 may be the external phase of the particle (also called bark).
- the polymer particles may be at least two-phase and have a core / bark structure.
- the softness of the polymer Pi can be reinforced by choosing a polymer Pi having a Tgi of less than 20 ° C, preferably less than 5 ° C and more preferably still lower than 0 ° C.
- the hard nature of the polymer P 2 can be reinforced by choosing a polymer P 2 having a Tg 2 greater than 60 ° C, preferably greater than 70 ° C and more preferably still greater than 80 ° C.
- the polymer Pi represents 60 to 90% by weight of the particles and the polymer P 2 represents 10 to 40% by weight of the particles.
- the first phase of the polymer particles according to the invention is obtained by polymerization of one or more monomers and at least one crosslinking agent.
- the second phase of the polymer particles according to the invention can be obtained by polymerization of one or more monomers and optionally of one or more crosslinking agents.
- the presence of a crosslinking agent in the first phase may in particular make it possible to structure said particle by crosslinking and in particular the first phase of said particle, which makes it possible to have a composition capable of forming a film having two glass transition temperatures of controlled and reproducible manner.
- the polymer P 1 may comprise 0.5 to 10%, preferably 1 to 7%, more preferably 2 to 5% by weight of units obtained by polymerization of a crosslinking agent, preferably chosen from group (II).
- the polymer Pi can comprise:
- the polymer P 2 can comprise 95 to 99.5%, preferably 97 to 99%, more preferably 100% by weight of units obtained by polymerization of at least one monomer chosen from the group (I ).
- the polymer P 2 may comprise 0.5 to 5%, preferably 1 to 3% by weight of units obtained by polymerization of a crosslinking agent, preferably chosen from the group (II).
- the monomers of group (I) can be selected from alkyl (Ci-Ci 6) esters of (meth) acrylic acid such as methyl (meth) acrylate, (meth) ethyl acrylate and butyl (meth) acrylate, hydroxy-alkyl esters of (meth) acrylic acid, vinyl esters of linear or branched carboxylic acids such as vinyl acetate and vinyl stearate, styrene, alkylstyrenes such as methylstyrene, haloalkylstyrenes such as chloromethylstyrene, (meth) acrylamide, acrylonitrile, vinyl chloride, (meth) acrylic acids and their derivatives such as anhydrides, monomers containing acids or basic such as itaconic acid, fumaric acid, crotonic acid, maleic acid, silane (meth) acrylic or vinyl monomers such as methacryloxypropyl triethoxy or tri
- the crosslinking agents of the group (II), within the meaning of the present application, can be chosen from the following monomers: allyl esters or (Cr Ci6) alkyl esters of monocarboxylic or dicarboxylic acids, such as allyl acrylate allyl methacrylate, diallyl maleate or phthalate and dimethyl maleate, conjugated dienes such as butadiene and isoprene, polyol poly (meth) acrylates such as ethylene glycol dimethylacrylate or triethylene glycol, 1,3-1,4-butylene glycol dimethylacrylate, 1,4-butanediol diacrylate and pentaerythritol tetraacrylate, trimethylolpropane triacrylate, polyvinylbenzenes such as divinylbenzene or trivinylbenzene and polyallyl derivatives such as triallyl cyanurate , triallyl isocyanurate and triallyl trimesate, and mixtures thereof.
- the crosslinking agents of the group (II) of the polymer Pi are chosen from diallyl maleate, dimethylmaleate, 1,4-butanediol diacrylate, and mixtures thereof.
- the monomer of the group (I) of the polymer P 2 is methyl methacrylate.
- the polymer P 2 of the aqueous dispersion according to the invention may contain at least 91%, preferably at least 95% and even more preferably 100% by weight of units obtained by polymerization of hydrophobic monomers.
- levels of hydrophobic monomers can allow, during the formation of the corresponding film, to obtain a hard film, non-tacky and water-resistant. These properties are, on the contrary, altered when the outer layer of the particles contains more than 10% of hydrophilic monomers.
- the hydrophobic character of a monomer is defined as its insolubility in water or its lack of affinity for water.
- a polymer consists of hydrophobic monomers, said polymer is also considered hydrophobic.
- the hydrophobicity of a polymer can be defined using the solubility parameter ⁇ described in "Properties of Polymers” by DW Van Krevelen, 1990, 3rd edition, page 200. This parameter classify the different polymers according to their affinity for water. According to the invention, a polymer is hydrophobic if its ⁇ is less than 26.
- the second phase of the polymer particles of the present invention does not contain units obtained by polymerization of monomers comprising an acid function.
- the polymer particles according to the invention comprise an intermediate phase, formed by a polymer P ,, interposed between the first phase and the second phase.
- the polymer P, of the intermediate phase has a glass transition temperature Tg, between 20 and 60 ° C.
- the polymer P may in particular be formed by polymerization in the presence of a crosslinking agent.
- the polymer Pi may comprise 90 to 99.5%, preferably 93 to 99%, more preferably 95 to 98% by weight of units obtained by polymerization of at least one monomer chosen from group (I).
- the polymer P 1 may comprise 0.5 to 10%, preferably 1 to 7%, more preferably 2 to 5% by weight of units obtained by polymerization of a crosslinking agent chosen from group (II).
- a crosslinking agent chosen from group (II) chosen from group (II).
- the monomers of the group (I) of the polymer P are chosen from butyl acrylate, methyl methacrylate, and mixtures thereof.
- the crosslinking agents of the group (II) of the polymer P are chosen from diallyl maleate, dimethylmaleate and 1,4-butanediol diacrylate, and mixtures thereof.
- the multiphase particles of polymers are substantially spherical and have a size of between 15 and 300 nanometers, preferably between 30 and 100 nanometers.
- the multiphase particles of polymers may in particular be present in the aqueous dispersion according to the invention in a content of between 25 and 70% by weight, preferably between 30 and 70% by weight, relative to the weight of the aqueous dispersion.
- the aqueous dispersion of multiphase particles according to the invention further comprises at least one surfactant.
- the surfactant makes it possible in particular to stabilize the suspension of the multiphasic particles of polymers in the aqueous phase.
- the surfactant used in the dispersion according to the invention is an amino acid derivative, such as in particular a derivative of sarcosinic acid or glutamic acid.
- the surfactant derived from amino acid may in particular be chosen from:
- the surfactant is chosen from sodium lauroylsarcosinate, sodium V-myristoylsarcosinate and sodium lauroylglutamate, preferably sodium lauroylsarcosinate.
- a surfactant derived from amino acids in the aqueous dispersions according to the invention makes it possible, in particular, to prepare aqueous dispersions of polymers which make it possible to obtain films having improved mechanical properties and in particular better elasticity and better strength. at break and better deformation at break.
- the surfactants derived from amino acids have a very low toxicity to the environment (these surfactants are biodegradable) but also for humans. This low toxicity is therefore an asset for the applications of the film according to the invention on the skin, wounds and / or mucous membranes.
- these surfactants one can also cite their compatibility with the pH of the skin and their low irritating potential.
- the Applicant has found, surprisingly, that it was possible to further optimize the properties of the film obtained after application of the film-forming composition by adjusting the concentration and the nature of the surfactant. Indeed, when the concentration of surfactant is too low, the film can lose elasticity and become brittle. Conversely, when the surfactant concentration is too high, the film may tend to become opaque and turn white. Indeed, it has been found, when the molar monomer to surfactant ratio is of the order of 30 or less than 30, the film obtained tends to become white and when this ratio is of the order of 190 or greater than 190 , the resulting film has a tendency to crack.
- the concentration of the surfactant in the aqueous dispersion according to the invention is preferably between 0.1 and 5% by weight, relative to the dry matter weight of the aqueous dispersion, preferably between 0.4 and 5% by weight. weight, and even more preferably between 0.7 and 2% by weight.
- the aqueous phase of the dispersion according to the invention may optionally comprise an oxidation / reduction system which makes it possible to promote the initiation of the polymerization.
- the oxidation / reduction system may be chosen from tert-butyl hydroperoxide / sodium bisulfite to which sodium sulfoxylate formaldehyde, potassium persulfate / sodium bisulfite, to which may be added, may be added.
- sodium sulphoxylate formaldehyde, ammonium persulfate / sodium bisulfite to which sodium sulphoxylate formaldehyde, potassium persulfate / sodium hydroxymethanesulphinate, and mixtures thereof are added.
- the preferred redox / reductant system is potassium persulfate / sodium bisulfite and sodium sulfoxylate formaldehyde.
- the oxidant and reducing agent concentration in the aqueous dispersion according to the invention may be between 0.01 and 5% by weight, preferably between 0.1 and 2% by weight, relative to the dry weight of the dispersion. aqueous.
- the aqueous phase of the dispersion according to the invention may also comprise a pH regulator which may in particular make it possible to adjust the pH so as to optimize the polymerization.
- a pH regulator used in the present invention are those commonly used by those skilled in the art. Such regulators are described in the following publications: CRC Handbook of Chemistry and Physics 76 th ed. (page 8- 42) Bower, VE and RGJ Res. Nat. Off. Stand. 55, 197, 1955 and Bats RG and Bower VE Anal. Chem., 28, 1322, 1956.
- the pH regulator is obtained by mixing in various proportions aqueous 0.1 M solutions of KH 2 PO 4 (potassium dihydrogenphosphate) and NaOH (sodium hydroxide) as described in FIG. Handbook of Chemistry and Physics, 76th ed. Chapter 8, pp. 8-42.
- KH 2 PO 4 potassium dihydrogenphosphate
- NaOH sodium hydroxide
- 50 ml of KH 2 PO 4 (0.1 M) and 5.6 ml of NaOH (0.1 M) are mixed in a 100 ml flask. and the volume is made up to 100 mL with deionized water.
- pH 7.0 regulator 50 ml of KH 2 PO 4 (0.1 M) and 29.1 ml of NaOH (0.1 M) are mixed in a 100 ml flask and the volume is 100 mL with deionized water.
- pH 7.5 regulator 50 ml of KH 2 PO 4 (0.1 M) and 40.9 ml of NaOH (0.1 M) are mixed in a 100 ml flask and the volume is 100 mL with deionized water.
- the pH regulator can also control the acid-base form of the surfactant.
- the surfactants derived from amino acids can be in two forms depending on the pH of the reaction medium:
- the surfactant is in its basic form, which corresponds to a pH of the aqueous dispersion greater than one unit above the pKa of the surfactant used (pH> pKa +1).
- the pka of the surfactants derived from amino acids within the meaning of the present invention must be lower than the pH of the final emulsion.
- the pKa may especially be between 2 and 7 and preferably between 3 and 5.
- the concentration of pH regulator in the aqueous dispersion may especially be between 5 mmol / L and 100 mmol / L, preferably between 10 mmol / L. and 15 mmol / L, the concentration being expressed in moles of pH regulator per liter of aqueous dispersion.
- a buffer solution having a pH of between 5.8 and 8.0 may, for example, be prepared from 50 ml of a solution of potassium dihydrogenphosphate ( 0.1 molar) + x mL of NaOH (0.1 molar), where x is a tabulated value as a function of the desired pH.
- the aqueous dispersion according to the invention may comprise, in addition to the components mentioned above, one or more pharmaceutical or cosmetic agents (or active agents) such as, in particular, anti-bacterial agents, antiseptics, anti-virals, antifungal agents. , painkillers, anti-inflammatories, healing agents, moisturizers, depigmenting agents, keratolytic agents, restructuring agents, anesthetics and sunscreens.
- pharmaceutical or cosmetic agents or active agents
- pharmaceutical or cosmetic agents such as, in particular, anti-bacterial agents, antiseptics, anti-virals, antifungal agents. , painkillers, anti-inflammatories, healing agents, moisturizers, depigmenting agents, keratolytic agents, restructuring agents, anesthetics and sunscreens.
- the active agents that can be introduced into the composition according to the invention can be chosen from: anti-bacterials such as Polymyxin B, penicillins (Amoxycillin), clavulanic acid, tetracyclines, Minocycline, chlorotetracycline, aminoglycosides, Amikacin, gentamicin, neomycin, silver and its salts (silver sulfadiazine), probiotics;
- anti-bacterials such as Polymyxin B, penicillins (Amoxycillin), clavulanic acid, tetracyclines, Minocycline, chlorotetracycline, aminoglycosides, Amikacin, gentamicin, neomycin, silver and its salts (silver sulfadiazine), probiotics;
- antiseptics such as sodium mercurothiolate, eosin, chlorhexidine, phenylmercury borate, hydrogen peroxide, Dakin liquor, triclosan, biguanide, hexamidine, thymol, Lugol, Povidone iodine, Merbromine, Benzalkonium and Benzethonium Chloride, ethanol, isopropanol;
- anti-virals such as Aciclovir, Famciclovir, Ritonavir;
- antifungals such as polyenes, Nystatin, Amphotericin B, Natamycin, imidazoles (Miconazole, Ketoconazole, Clotrimazole, Ecconazole,
- anti-pain agents such as paracetamol, codeine, dextropropoxyphene, tramadol, morphine and its derivatives, corticosteroids and derivatives; anti-inflammatories such as glucocorticoids, nonsteroidal anti-inflammatory drugs, aspirin, ibuprofen, ketoprofen, flurbiprofen, diclofenac, aceclofenac, ketorolac, meloxicam, piroxicam, tenoxicam, Naproxen, Indomethacin, Naproxcinod, Nimesulide, Celecoxib, Etoricoxib, Parecoxib, Rofecoxib, Valdecoxib, Phenylbutazone, Niflumic acid, Mefenamic acid;
- the active agents promoting healing such as retinol, vitamin A, vitamin E, N-acetyl-hydroxyproline, extracts of Centella Asiatica, papain, silicones, essential oils of thyme, niaouli, rosemary and of sage, hyaluronic acid, synthetic polysulfated oligosaccharides having 1 to 4 units such as the potassium salt of octasulfated sucrose, the silver salt of octasulfated sucrose or sucralfate, Allantoin;
- moisturizing agents such as hyaluronic acid, urea, glycerol, fatty acids, modulators of aquaporins, vegetable oils, chitosan, certain sugars including sorbitol, butters and waxes; depigmenting agents such as kojic acid (Kojic Acid SL®-Quimasso (Sino Lion)), Arbutin (Olevatin® - Quimasso (Sino Lion)), the mixture of palmitoylpropyl of sodium and white water lily extract (Sepicalm® - Seppic), undecylenoyl phenylalanine (Sepiwhite® - Seppic), licorice extract obtained by fermentation of Aspergillus and ethoxydiglycol (Gatuline Whitening® - Gattefossé), octadecenedioic acid (ODA White® - Sederma) alpha-arbutin (Alpha-arbutin®, SACI-
- anesthetics such as benzocaine, lidocaine, dibucaine, pramoxine hydrochloride, bupivacaine, mepivacaine, prilocaine, etidocaine; - sunscreens, such as chemical filters (Oxybenzone, Sulisobenzone, Dioxybenzone, Tinosorb S®, Avobenzone, 2-ethoxyethyl p-methoxycinnamate, Uvinul® A +, Mexoryl® XL, Methoxycinnamate or octyl octinoxate, Salicylate or octisalate d octyl, octyl triazone or Uvinul® T 150, methyl salicylate, meradimate, enzacamene, MBBT or Tinosorb® M, octyl cyanophenylcinnamate or Parsol® 340, para-aminobenzoic acid, Ensulizo
- the active agent into the inner phase or into the outer phase of the multiphasic particle of polymers or to leave it free in solution.
- the phase in which it is desired to incorporate the active agent according to the chemical properties of the active agent. It will also be possible to choose the phase in which the active agent is integrated depending on whether it is desired that the latter be salted out or not.
- the active in one of the phases of the multiphase particles of polymers it may in particular be introduced simultaneously to the monomers that form the polymer of this phase.
- the active agent incorporated in the internal phase of the multiphasic particle of polymers is a sunscreen, such as Parsol® MCX.
- This sunscreen is hydrophobic and should preferably stay on the surface of the skin, ie not to be salted out, in order to be able to exert its filtering properties and protect the skin from UV-B rays.
- Incorporation of Parsol® MCX in the internal phase of the particle may, for example, allow good dispersion and good persistence of the active agent on the skin once the film has been applied thereto.
- a dispersion of multiphase particles of polymers comprising a sunscreen in their internal phase is applied to the skin, a film particularly resistant to water and effectively protecting the skin from the sun is obtained. This may in particular allow to avoid repeated applications of sunscreen, while providing optimal sun protection to the user. Indeed, it has been shown that no release of sunscreen is observed when the films obtained are washed with water.
- the active agent is free in solution in the aqueous dispersion of multiphase particles of polymers or in the composition comprising said dispersion.
- an active agent such as in particular a sunscreen, intended to protect a surface, such as the skin
- the active agent is thus better dispersed within the film (more homogeneous dispersion) and thus adheres better to the skin, which gives the skin excellent protection against the sun's rays.
- aqueous dispersion according to the invention may comprise, in addition to the components mentioned above, one or more physiologically acceptable additives such as, for example, perfumes, flavors, dyes, pigments, matting agents, rheological agents, preservatives.
- physiologically acceptable additives such as, for example, perfumes, flavors, dyes, pigments, matting agents, rheological agents, preservatives.
- the aqueous dispersion according to the invention can in particular be obtained by emulsion polymerization according to the techniques well known to those skilled in the art.
- the surfactant makes it possible to form monomer droplets (also called micelles) within which the polymerization takes place.
- the soft-matter polymer P 1 constituting, for example, the internal phase of the particles in the presence of a crosslinking agent, preferably chosen from the group (II). ), and then proceed to the preparation of the polymer P 2 hard character constituting the outer phase of the particles.
- a crosslinking agent preferably chosen from the group (II).
- the polymer particle comprises an intermediate phase formed by a polymer Pi
- the polymerization reaction is preferably carried out under an inert atmosphere at a temperature between 25 and 150 ° C depending on the nature of the oxidation / reducing system used.
- the monomers are added in the aqueous phase, either in pure form or in the form of a pre-emulsion with a part of the water and at least one surfactant, over a period of time ranging from for a preparation of about 100 grams of aqueous dispersion, between 10 minutes and 3 hours, preferably between 15 and 90 minutes.
- compositions comprising, in a physiologically acceptable medium, an aqueous dispersion of multiphase particles of polymers according to the invention.
- physiologically acceptable medium is meant, within the meaning of the present invention, a medium that is compatible with the skin, mucous membranes, wounds, lesions and / or skin disorders.
- the physiologically acceptable medium may include water. According to a preferred embodiment, the physiologically acceptable medium does not include any other solvent than water.
- composition according to the invention may comprise, in addition to the aqueous dispersion of multiphase particles, one or more pharmaceutical or cosmetic agents (or active agents) as defined above.
- composition according to the invention may also comprise one or more physiologically acceptable additives as defined above.
- the film-forming composition according to the invention comprises only the aqueous dispersion of multiphasic particles of polymers described above. According to another preferred embodiment, the film-forming composition according to the invention comprises:
- the film-forming composition according to the invention is liquid, that is to say that it flows under its own weight.
- the film-forming compositions according to the invention may, for example, be carried out by adding, with stirring, the various active agents and additives in a dispersion of multiphase particles of polymers according to the invention, or vice versa, by adding a dispersion of multiphase particles of polymers according to the invention in an aqueous base containing the various active agents and additives.
- the active agents and / or the physiologically acceptable additives can be incorporated in the inner phase or in the outer phase of the multiphasic particle of polymers or they can be free in solution in the composition according to the invention.
- the invention also provides, according to another aspect of the invention, a film having at least two different Tg, said film comprising multiphase particles of polymers and a surfactant, said polymer particles comprising at least two distinct phases:
- said surfactant is selected from amino acid derivatives and wherein the polymer Pi is formed by polymerization in the presence of a crosslinking agent.
- the film has two distinct Tg which can be measured experimentally and which are in particular of the same order of magnitude as the Tg of each of the two phases of the polymer particles constituting said film.
- Tg the introduction of certain pharmaceutical agents during the preparation of one of the phases of the particle may lead to a change in the Tg of the phase in which the pharmaceutical agent is introduced. In this case, a difference can be observed between one of the Tg of the film measured experimentally and that measured in the absence of said agent.
- the glass transition temperature of the film is understood to mean the glass transition temperature of the previously unheated (or non-annealed) film measured by AMD (Dynamic Mechanical Analysis also known as DMTA for Mechanical Thermodynamic Analysis). at 1 Hz according to the method described below.
- film not previously heated is meant, in the sense of the present invention, a film which has not been heated above 40 ° C.
- the film may in particular be obtained by applying the film-forming composition according to the invention directly to a surface, followed by evaporation of the water.
- the composition can in particular be applied in a single layer on said surface.
- a layer of 10 to 300 ⁇ m of the film-forming composition is produced.
- composition may be applied by any means known to those skilled in the art such as a spray, a pen, a spatula, and especially with a brush.
- a spray a pen
- a spatula a brush
- the Applicant has found that the film obtained with the aqueous dispersions according to the invention has a particularly fast drying time, generally less than two minutes. This property is particularly suitable for producing films in situ, for example on the skin.
- the film also has excellent water resistance.
- the film obtained after drying has excellent mechanical properties determined by the method described below:
- Films with a thickness of about 0.7 mm are obtained by evaporating a column of film-forming composition according to the present invention, about 2 mm high in a Teflon mold.
- Dumbbells in the form of DIN 53504S3A (useful length 12 mm, width 2 mm) corresponding to ISO 527-3 are obtained by punching the sheet about 0.7 mm thick using a punch.
- the mechanical measurements are carried out at a pulling speed of 10 mm / min using an Instron tensile machine equipped with a 500 N force sensor.
- the films of the present invention can have a good deformation at break that can go beyond 150%, as well as an excellent breaking strength of up to 5 MPa.
- the films of the present invention have an elastic regime with an elastic modulus of the order of 50 MPa and a wide plastic domain with a plastic deformation threshold of the order of 3 MPa.
- the film has a very good adhesion to the substrate on which it is formed without however having a tacky feel (surface tack or "tack" in English).
- the film also has good friction resistance.
- the film may be applied to a surface to be protected.
- another object of the invention is the use of the previously described film to protect skin surfaces, mucous membranes, wounds, lesions and / or skin conditions.
- the film according to the invention therefore finds application in the fields of dermatology and cosmetics. It may also be envisaged to apply the film according to the invention to the integuments.
- the film according to the invention also has applications in the field of coatings of all types of materials, such as for example leather, plastic, plaster, cardboard or paper or composite materials such as concrete or wood. .
- the previously described film-forming composition can be applied to the surface that it is desired to protect. After about two minutes, once the water has completely evaporated, the treated surface is covered with an elastic film.
- the present invention is further illustrated in the non-limiting examples described below.
- MMA methyl methacrylate
- ABu n-butyl acrylate
- BDA 1,4-butanediol diacrylate
- DAM diallyl maleate
- SB sodium bisulfite
- KPS potassium persulfate
- SSF sulfoxylate formaldehyde sodium APS: ammonium persulfate
- Preparation B 2.8% by weight aqueous solution of the initiator SB (sodium bisulfite).
- Example 1 (Comparative) Preparation of an aqueous dispersion of monophasic polymer particles with a surfactant derived from amino acid
- Example 3 (Comparative) Preparation of an aqueous dispersion of multiphasic particles of polymers with sodium dodecyl sulfate surfactant
- Example 2 The procedure of Example 1 is followed but using Preparation D in place of Preparation C. An emulsion 3 is obtained which is converted into emulsion 4 following the procedure of Example 2.
- Dynamic Light Scattering (DLS) measurements were performed using an ALV / CGS3 goniometer equipped with a multi- ⁇ ALV / LSE 5004 correlator and a He-Ne laser at a wavelength of 632.8 nm. The measurements were made on samples of 10 mm diameter over seven angles of diffusion ranging from 60 ° to 120 ° with an incrementation of 10 °. The system was maintained at 23 ° C. Each sample was prepared as follows: 20 ml of Milli-Q® water, filtered twice on a 0.22 ⁇ porosity syringe filter are placed in a glass vial. 5 ⁇ of emulsion are injected with a micropipette. These samples are then analyzed in sequences of 100 seconds for each angle value, the collected data are then processed by cumulant analysis.
- DLS Dynamic Light Scattering
- the particles are spherical and have a mean diameter of about 36-38 nm measured by DLS.
- Emulsion 2 has a pH of between 6 and 7 and the proportion of solids is about 40%.
- the dispersed polymer particles are spherical and have an average diameter of about 38-42 nanometers measured by DLS.
- the soft phase of the particles consisting of a mixture of butyl acrylate and methyl methacrylate, represents approximately 80% of the total weight of the particles and the hard phase, consisting of methyl methacrylate, represents approximately 20% of the total weight of the particles. total weight of the particles.
- the particles are spherical and have an average diameter of about 47-49 nm measured by DLS.
- Films of thickness about 0.7 mm are obtained by evaporating an emulsion column 2 of height about 2 mm in a Teflon mold.
- DIN 53504S3A dumbbells (useful length 12 mm, width 2 mm) corresponding to the ISO 527-3 standard are obtained by punching the sheet about 0.7 mm thick with a punch. room.
- the mechanical measurements were carried out at a pulling speed of 10 mm / min using an Instron tensile machine equipped with a force sensor of 500 N and gave the following results: From rectangular samples cut 10 mm x 25 mm in the same film, dynamic mechanical analysis (AMD) measurements are carried out using a DMA 2980 analyzer (TA instruments) in the tension geometry of films by applying a -voltage of 0.01 N and operating at 1 Hz.
- the values of Tg are the temperatures at which the dissipation factor, tan (delta) passes through a maximum. These values are measured at first heating at 3 ° C / min on unheated films.
- the films obtained with emulsion 1 have the following characteristics: - Stress at break: 0.25 MPa
- the films obtained with emulsion 2 have the following characteristics:
- the mechanical measurements made on the films obtained with the emulsion 1 show that the films break for a lower stress, of the order of 0.25 MPa, than for the films obtained with the emulsion 2 according to the invention. In addition, for the films obtained with emulsion 1, plastic deformation is observed even for low applied stresses.
- This example shows that films made from monophasic particles (emulsion 1) have lower mechanical properties than films obtained from particles of multiphasic structure according to the invention (emulsion 2).
- the mechanical measurements made on the films obtained with the emulsion 4 show that the films break for a lower stress, of the order of 0.85 MPa, than for the films obtained with the emulsion 2 according to the invention.
- plastic deformation is observed even for low applied stresses.
- films made from multiphase particles have superior mechanical properties when using a derivative amino acid such as sodium N-lauroylsarcosinate as surfactant rather than SDS as in the prior art.
- Example 5 Incorporation of active after polymerization (free in solution).
- Parsol® MCX ethylhexyl methoxycinnamate
- Example 6 Incorporation of active in the internal phase of the polymer particles.
- Example 1 The procedure of Example 1 is followed except that Preparation E is used in place of Preparation C and the reactor and flasks are protected from light by aluminum foil.
- the emulsion obtained is then converted according to the procedure of Example 2, protecting the reactor and the flasks with aluminum foil.
- the particle size of the emulsion obtained is about 36-38 nm.
- Example 7 Incorporation of Active in the External Phase of the Polymer Particles
- Preparation H is used in place of Preparation G and the reactor and flasks are protected from light by aluminum foil.
- the final size of the particles measured by light scattering (DLS) is about 40-44 nm.
- a film is made from this emulsion under conditions identical to those of Example 4, but with the exclusion of light.
- the values of Tg measured in the same way as in Example 4 are:
- Elongational elastic module 10 MPa Plastic deformation threshold: 1 MPa
- EXAMPLE 8 Comparative Measurement of the Transmittance of the Films Formed from the Emulsions of Examples 2 and 7
- the transmittance of the film obtained in Example 7 is measured in the visible at 530 nm and in the UVB at 308 nm using a Jasco V-530 spectrometer by placing the film as close as possible to the detector. The same measurement is made on a control film free of sunscreen, made according to Example 2.
- the film-forming composition of Example 2 is applied with a brush in a single layer of 150 ⁇ m.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Manufacturing & Machinery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112014030566A BR112014030566A2 (pt) | 2012-06-08 | 2013-06-07 | dispersão aquosa de partículas de polímero, composição de formação de filme contendo a mesma e usos das mesmas |
US14/405,897 US9642790B2 (en) | 2012-06-08 | 2013-06-07 | Aqueous dispersion of polymer particles, film-forming composition containing same and uses thereof |
CN201380042121.6A CN104684532B (zh) | 2012-06-08 | 2013-06-07 | 聚合物颗粒的水分散体,包含该水分散体的成膜组合物及其用途 |
JP2015515575A JP6294313B2 (ja) | 2012-06-08 | 2013-06-07 | ポリマー粒子の水性分散液、それを含有する膜形成組成物、及びその使用 |
CA2875604A CA2875604A1 (fr) | 2012-06-08 | 2013-06-07 | Dispersion aqueuse de particules de polymeres, composition filmogene la contenant et ses utilisations |
EP13731398.7A EP2861201A1 (fr) | 2012-06-08 | 2013-06-07 | Dispersion aqueuse de particules de polymeres, composition filmogene la contenant et ses utilisations |
HK15104190.3A HK1203415A1 (en) | 2012-06-08 | 2015-04-30 | Aqueous dispersion of polymer particles, film-forming composition containing same and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1255393A FR2991684B1 (fr) | 2012-06-08 | 2012-06-08 | Dispersion aqueuse de particules de polymeres, composition filmogene la contenant et ses utilisations |
FR1255393 | 2012-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013182828A1 true WO2013182828A1 (fr) | 2013-12-12 |
Family
ID=46785641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2013/051325 WO2013182828A1 (fr) | 2012-06-08 | 2013-06-07 | Dispersion aqueuse de particules de polymeres, composition filmogene la contenant et ses utilisations |
Country Status (9)
Country | Link |
---|---|
US (1) | US9642790B2 (fr) |
EP (1) | EP2861201A1 (fr) |
JP (1) | JP6294313B2 (fr) |
CN (1) | CN104684532B (fr) |
BR (1) | BR112014030566A2 (fr) |
CA (1) | CA2875604A1 (fr) |
FR (1) | FR2991684B1 (fr) |
HK (1) | HK1203415A1 (fr) |
WO (1) | WO2013182828A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015153461A1 (fr) * | 2014-04-01 | 2015-10-08 | Isp Investments Inc. | Polymères dérivés de lactame de vinyle, compositions de ceux-ci ayant une résistance à l'eau améliorée et leurs procédés d'utilisation |
JP6498716B2 (ja) * | 2017-04-07 | 2019-04-10 | 花王株式会社 | 地盤の改良工法 |
GB2580910A (en) * | 2019-01-28 | 2020-08-05 | Synthomer Uk Ltd | Self-supported elastomeric film having self-healing properties made from a polymer latex |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0398489A2 (fr) * | 1989-04-10 | 1990-11-22 | Minnesota Mining And Manufacturing Company | Emulsion filmogène contenant de l'iode et procédés d'utilisation |
WO1994004581A1 (fr) * | 1992-08-13 | 1994-03-03 | Ppg Industries, Inc. | Latex a base aqueuse, adaptes a l'application par pulverisation |
JP2002138394A (ja) * | 2000-11-01 | 2002-05-14 | Gantsu Kasei Kk | 防湿性紙塗工用共重合体エマルジョン |
WO2009016053A1 (fr) * | 2007-07-30 | 2009-02-05 | Basf Se | Polymère cœur-écorce |
US20100021409A1 (en) | 2008-02-11 | 2010-01-28 | Ali Abdelaziz Alwattari | Film Forming Personal Care Compositions |
WO2012006402A1 (fr) * | 2010-07-09 | 2012-01-12 | Lubrizol Advanced Materials, Inc. | Epaississants structurés à base d'un copolymère d'acrylate |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4843661B1 (fr) * | 1970-12-29 | 1973-12-20 | ||
JP2721596B2 (ja) * | 1990-07-18 | 1998-03-04 | 株式会社クラレ | アクリル系重合体凝固組成物、その製法およびその成形物 |
FR2767835B1 (fr) * | 1997-08-28 | 2003-09-12 | Atochem Elf Sa | Latex ne contenant ni composes organiques volatils ni agents de coalescence et pouvant former un film a basse temperature |
FR2790263A1 (fr) * | 1999-02-26 | 2000-09-01 | Atochem Elf Sa | Materiaux composites contenant une couche d'un film antichoc |
NO20002309L (no) * | 1999-05-12 | 2000-11-13 | Hoffmann La Roche | Fotostabile kosmetiske lysavskjermende sammensetninger |
AU2007202470B2 (en) * | 2006-06-13 | 2012-09-13 | Rohm And Haas Company | Multistage polymer composition and method of use |
JP5114089B2 (ja) * | 2007-04-24 | 2013-01-09 | 株式会社マンダム | 乳液状皮膚化粧料 |
-
2012
- 2012-06-08 FR FR1255393A patent/FR2991684B1/fr not_active Expired - Fee Related
-
2013
- 2013-06-07 CA CA2875604A patent/CA2875604A1/fr not_active Abandoned
- 2013-06-07 CN CN201380042121.6A patent/CN104684532B/zh not_active Expired - Fee Related
- 2013-06-07 JP JP2015515575A patent/JP6294313B2/ja not_active Expired - Fee Related
- 2013-06-07 WO PCT/FR2013/051325 patent/WO2013182828A1/fr active Application Filing
- 2013-06-07 EP EP13731398.7A patent/EP2861201A1/fr not_active Withdrawn
- 2013-06-07 BR BR112014030566A patent/BR112014030566A2/pt not_active Application Discontinuation
- 2013-06-07 US US14/405,897 patent/US9642790B2/en not_active Expired - Fee Related
-
2015
- 2015-04-30 HK HK15104190.3A patent/HK1203415A1/xx unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0398489A2 (fr) * | 1989-04-10 | 1990-11-22 | Minnesota Mining And Manufacturing Company | Emulsion filmogène contenant de l'iode et procédés d'utilisation |
US5173291A (en) | 1989-04-10 | 1992-12-22 | Minnesota Mining And Manufacturing Company | Film-forming emulsion containing iodine and methods of use |
WO1994004581A1 (fr) * | 1992-08-13 | 1994-03-03 | Ppg Industries, Inc. | Latex a base aqueuse, adaptes a l'application par pulverisation |
JP2002138394A (ja) * | 2000-11-01 | 2002-05-14 | Gantsu Kasei Kk | 防湿性紙塗工用共重合体エマルジョン |
WO2009016053A1 (fr) * | 2007-07-30 | 2009-02-05 | Basf Se | Polymère cœur-écorce |
US20100021409A1 (en) | 2008-02-11 | 2010-01-28 | Ali Abdelaziz Alwattari | Film Forming Personal Care Compositions |
WO2012006402A1 (fr) * | 2010-07-09 | 2012-01-12 | Lubrizol Advanced Materials, Inc. | Epaississants structurés à base d'un copolymère d'acrylate |
Non-Patent Citations (5)
Title |
---|
"CRC Handbook of Chemistry and Physics", pages: 8 - 42 |
"Handbook of Chemistry and Physics", pages: 8 - 42 |
BATES R.G.; BOWER V.E., ANAL. CHEM., vol. 28, 1956, pages 1322 |
BOWER, V.E.; BATES R.G., J. RES. NAT. BUR. STAND., vol. 55, 1955, pages 197 |
D.W. VAN KREVELEN: "Properties of polymers", 1990, pages: 200 |
Also Published As
Publication number | Publication date |
---|---|
CN104684532B (zh) | 2017-04-26 |
EP2861201A1 (fr) | 2015-04-22 |
HK1203415A1 (en) | 2015-10-30 |
US20150174042A1 (en) | 2015-06-25 |
US9642790B2 (en) | 2017-05-09 |
CN104684532A (zh) | 2015-06-03 |
BR112014030566A2 (pt) | 2017-06-27 |
FR2991684A1 (fr) | 2013-12-13 |
JP2015519376A (ja) | 2015-07-09 |
FR2991684B1 (fr) | 2015-05-22 |
CA2875604A1 (fr) | 2013-12-12 |
JP6294313B2 (ja) | 2018-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2688651B1 (fr) | Composition contenant une cellulose, une huile vegetale et un solvant volatil, son utilisation comme pansement | |
EP1296640B1 (fr) | Utilisation comme epaississants en cosmetique de copolymeres neutralises comportant des motifs d'acide faible et des motifs d'acide fort | |
EP3548529B1 (fr) | Procédé de préparation de microcapsules de taille contrôlée comprenant une étape de photopolymérisation | |
EP2688650A1 (fr) | Composition filmogene contenant un filtre solaire, son utilisation pour le traitement des cicatrices | |
EP0884047A1 (fr) | Utilisation de certains polymères polyamines comme agents anti-oxydants | |
FR3029785A1 (fr) | Dispersions stables comprenant des gouttes d'agent parfumant | |
FR2721209A1 (fr) | Composition de soin ou de maquillage comprenant une dispersion aqueuse de polymères. | |
WO2013175286A2 (fr) | Composition cosmetique contenant une dispersion de particules a base de polymere et de charges minerales | |
Wu et al. | Pickering emulsions-chitosan hydrogel beads carrier system for loading of resveratrol: Formulation approach and characterization studies | |
WO2013182828A1 (fr) | Dispersion aqueuse de particules de polymeres, composition filmogene la contenant et ses utilisations | |
EP3055031B1 (fr) | Utilisation en cosmetique de polymeres obtenus par polymerisation en emulsion inverse basse concentration | |
EP3223774B1 (fr) | Pansement ou patch adhésif à forte charge minérale | |
EP2793946B1 (fr) | Composition topique filmogène et son utilisation pour traiter ou prévenir l'onychophagie | |
WO2018178597A1 (fr) | Composition contenant un derive de cellulose, un plastifiant et un solvant volatil, et ses utilisations comme pansement | |
EP2498744B1 (fr) | Procede d'incorporation d'actifs dans un vernis a ongles et vernis a ongles ainsi prepare | |
CA2825974A1 (fr) | Formulation cosmetique contenant un copolymere amphiphile non hydrosoluble comme agent epaississant | |
FR2856925A1 (fr) | Nouveau patch cosmetique ou pharmaceutique, en particulier dermatologique et ses applications | |
FR2984166A1 (fr) | Composition topique filmogene et son utilisation pour traiter ou prevenir l'onychophagie | |
CA2972590C (fr) | Microparticules polymeriques | |
FR3135982A1 (fr) | Dispersions de gouttes contenant un polymère anionique et un polymère cationique (di)aminé | |
FR3135981A1 (fr) | Dispersions de gouttes contenant un polymère anionique et un polymère cationique aminé | |
JP2022051995A (ja) | 化粧料組成物 | |
FR3132431A1 (fr) | Composition de gel cosmetique comprenant des particules | |
WO2016005693A1 (fr) | Copolymeres cationiques statistiques, leur procede de synthèse et leur utilisation pour l'encapsulation d'ingrédients | |
WO2016005689A1 (fr) | Utilisation d'un homopolymere amine pour l'encapsulation d'ingredients, procede de synthese d'un homopolymere d'aema, et procede d'encapsulation d'ingredients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13731398 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015515575 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2875604 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14405897 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013731398 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014030566 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014030566 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141205 |